AC Immune says IND-enabling studies for Tau Morphomer program start in H1 2026

AC Immune SA

AC Immune SA

ACIU

0.00
  • AC Immune amended 2018 Tau Morphomer license and collaboration with Lilly to extend work on new lead candidates for Alzheimer’s disease and other neurodegenerative disorders.
  • IND-enabling studies are scheduled to start in H1 2026, with no clinical results presented yet.
  • Program aims to develop oral, brain-penetrant small molecules designed to slow or halt Tau-driven disease progression, based on preclinical evidence.
  • Amendment triggers CHF 10 million upfront payment, with another milestone due at Phase 1 dosing.
  • Deal terms keep AC Immune eligible for over CHF 1.7 billion in additional milestones, with low double-digit tiered royalties.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950103-26-005409), on April 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.